mRNA flu shots move into trials
Elie Dolgin • October 11, 2021
COVID-19 provided an opportunity to show that mRNA vaccines can work. Now, drug companies are racing to apply the technology platform for influenza.
Hot off the successful deployment of mRNA vaccines for the prevention of COVID-19, three leading drugmakers have moved seasonal flu vaccine candidates built with the technology into early clinical testing.
Continue reading at Nature Reviews Drug Discovery.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.